Albendazole: a Potent Inhibitor of Vascular Endothelial Growth Factor and Malignant Ascites Formation in OVCAR-3 Tumor-Bearing Nude Mice
article
OA: closed
CC0
Abstract
Abstract Purpose: Angiogenesis and vessel hyperpermeability are the two factors leading to the formation of ascites. Vascular endothelial growth factor (VEGF) plays a pivotal role in malignant ascites formation. We have recently shown that albendazole inhibits peritoneal growth of human colorectal cancer cells (HT-29). The present study was designed to find out if albendazole can suppress ascites formation in ascites-producing peritoneal carcinomatosis. Experimental design: Female nude mice bearing peritoneal tumors of human ovarian cancer cells (OVCAR-3) were treated with albendazole. Following i.p. inoculation and ascites development, mice were given i.p. albendazole (150 mg/kg) or the vehicle × 3 weekly for 4 weeks. Results: Whereas vehicle-treated mice developed overt ascites requiring repeated aspiration, ascites formation in the albendazole-treated mice was markedly suppressed. As a result of this, 7 of 10 mice from the control group had to be euthanized before the course of treatment was over. Suppressed ascites production and reduced tumor vascularity observed was a result of dramatic reduction in tumor VEGF production as revealed by profoundly lower VEGF ascites fluid and plasma levels. In vitro, incubation of SKOV-3 cells with various concentrations of albendazole led to significant dose-dependent inhibition of VEGF secretion. Examination of floating tumor cells collected from the peritoneal wash revealed profound down-regulation of VEGF mRNA in albendazole-treated mice. Conclusions: These findings suggest for the first time that in nude mice bearing OVCAR-3 peritoneal tumors, by inhibiting VEGF production, albendazole abolishes tumor angiogenesis and ascites formation.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
References (51)
- W1532183186 via openalex
- W1539571840 via openalex
- W1542216227 via openalex
- W1589068001 via openalex
- W1819048918 via openalex
- W1845506541 via openalex
- W1969453867 via openalex
- W1973514430 via openalex
- W1977953284 via openalex
- W1994062040 via openalex
- W1995637683 via openalex
- W1996724534 via openalex
- W1999972773 via openalex
- W2000292756 via openalex
- W2001282311 via openalex
- W2008119533 via openalex
- W2012812435 via openalex
- W2016298881 via openalex
- W2018033462 via openalex
- W2021645028 via openalex
- W2024529463 via openalex
- W2027238676 via openalex
- W2044502634 via openalex
- W2045222534 via openalex
- W2062594120 via openalex
- W2064726235 via openalex
- W2072721273 via openalex
- W2076424556 via openalex
- W2082419433 via openalex
- W2083028979 via openalex
- W2088719505 via openalex
- W2089264827 via openalex
- W2093696983 via openalex
- W2099499481 via openalex
- W2100470338 via openalex
- W2107579697 via openalex
- W2124275237 via openalex
- W2127039828 via openalex
- W2135172310 via openalex
- W2135638162 via openalex
- W2137881730 via openalex
- W2138843392 via openalex
- W2141820814 via openalex
- W2142874979 via openalex
- W2143872823 via openalex
- W2144720355 via openalex
- W2149734528 via openalex
- W2149973964 via openalex
- W2150478490 via openalex
- W2172019818 via openalex
- W2740725450 via openalex
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0
· commercial use OK